BCLSI
ACAD icon

Bain Capital Life Sciences Investors’s Acadia Pharmaceuticals ACAD Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-701,402
Closed -$11.2M – 35
2022
Q4 		$11.2M Buy
701,402
+90,879
+15% +$1.42M 1.25% 22
2022
Q3 		$9.99M Buy
610,523
+10,000
+2% +$162K 1.19% 21
2022
Q2 		$8.46M Buy
+600,523
New +$11.2M 0.99% 21

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bain Capital Life Sciences Investors's ACAD Position: Q1 2023 in Review

Bain Capital Life Sciences Investors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 701,402 shares — an estimated $11.2M sold.

Bain Capital Life Sciences Investors first reported a position in ACAD in Q2 2022 and held it in 3 quarters. The position peaked at $11.2M in Q4 2022. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

  • Bain Capital Life Sciences Investors reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 701,402 Acadia Pharmaceuticals shares in Q1 2023, an estimated $11.2M.
  • Bain Capital Life Sciences Investors first reported a position in Acadia Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Bain Capital Life Sciences Investors's Acadia Pharmaceuticals position peaked at $11.2M in Q4 2022.
  • 233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2023, filed 15 May 2023.